GLP Peptide Comparison: Semaglutide, Tirzepatide, Retatrutide, and Beyond

The GLP space has gotten complicated fast. Two years ago most people had heard of Ozempic and that was about it. Now there are six or more distinct compounds with meaningfully different receptor profiles, different strengths, different side-effect patterns, and different reasons someone would pick one over another. If you are trying to figure out which one makes sense for you, the noise is real.

This article is a straight educational breakdown. No hype, no protocol instructions - just a clear look at how each compound works, what it is best at, where the trade-offs live, and what the data actually shows about how they compare. The goal is to give you enough information to have an informed conversation with a provider or to walk into a protocol decision with your eyes open.

Why the Receptor Profile Is Everything

Before comparing compounds, it helps to understand what you are actually comparing. These peptides do not all work the same way. They activate different combinations of three receptors, and the receptor profile is the whole ballgame.

GLP-1 (glucagon-like peptide-1) is the foundational receptor in this class. When activated, it triggers glucose-dependent insulin release from the pancreas, suppresses glucagon (which reduces liver glucose output), slows gastric emptying to extend fullness, and acts on appetite-regulating areas of the brain to reduce hunger. Every compound in this article hits the GLP-1 receptor. That is the baseline.

GIP (glucose-dependent insulinotropic polypeptide) is where tirzepatide and retatrutide separate from semaglutide. GIP co-stimulates insulin release and directly modulates fat storage and release in adipose tissue. Research from the German Diabetes Center (DZD) in 2023 found that tirzepatide's insulin-stimulating effect in human pancreatic islets is driven primarily through the GIP receptor rather than the GLP-1 receptor - a finding that explains why dual agonists outperform pure GLP-1 agonists on both glycemic control and body composition. GIP also appears to attenuate some of the nausea associated with pure GLP-1 stimulation, which is clinically relevant for tolerability.

The glucagon receptor is what makes retatrutide a triple agonist and a different animal. Glucagon normally raises blood glucose, but at the receptor level it also drives significant increases in energy expenditure and fat burning. When you activate the glucagon receptor alongside GLP-1 and GIP, you get a compound that not only reduces calorie intake but also meaningfully increases calorie burning - which is why retatrutide's weight-loss numbers are the highest in the class at equivalent treatment durations.

The practical implication: a compound is not just "stronger" or "weaker" than another. It has a different profile - different strengths, different trade-offs, different best-fit use cases. That is what the rest of this article maps out.

Semaglutide: The Established Standard

Semaglutide (branded as Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus as an oral tablet) is the compound with the deepest clinical evidence base in this class. It shares 94% structural homology with human GLP-1 and binds selectively to the GLP-1 receptor.

How it works

Semaglutide activates the GLP-1 receptor, which produces four practical effects: glucose-dependent insulin secretion (insulin only releases when blood sugar is actually elevated, not indiscriminately), glucagon suppression that cuts hepatic glucose production, slowed gastric emptying that extends satiety, and central appetite modulation through hypothalamic GLP-1 receptors. The net result is a compound that lowers blood glucose intelligently, reduces hunger signaling in the brain, and extends the feeling of fullness after meals - all through a single receptor target.

What the clinical data shows

The STEP trial program established the standard clinical picture for injectable semaglutide. At the approved 2.4 mg weekly maintenance dose for weight management, participants lost approximately 15% of body weight over 68 weeks. The higher-dose STEP UP trial, which studied 7.2 mg weekly, showed 20.7% weight loss - substantially better than the standard dose and a signal that meaningful dose-response room exists above the currently approved ceiling.

For HbA1c reduction in type 2 diabetes, a weekly 1.0 mg dose over 40 weeks produced a 1.5 to 1.8 percentage point drop in glycated hemoglobin, which is clinically significant. Semaglutide is also the only compound in this comparison with an approved cardiovascular outcomes indication - it reduces the risk of heart attack, stroke, and cardiovascular death in type 2 diabetes patients with established heart disease. It has also received approval for metabolic-associated steatohepatitis (MASH), making it one of the more broadly indicated compounds in this class.

Side-effect profile

The most common side effects are gastrointestinal. In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), gastrointestinal disorders were reported by a clear majority of semaglutide-treated participants and by roughly half of those on placebo. Most are mild to moderate and self-limiting during the dose escalation period, with nausea, vomiting, diarrhea, and constipation the dominant complaints.

Serious adverse events are less common than the GI noise suggests, but they are more frequent on drug than on placebo. In STEP 1, serious adverse events occurred in 9.8% of semaglutide participants versus 6.4% on placebo, with the gap driven largely by serious gastrointestinal and hepatobiliary events. Gallbladder-related events are a documented risk across the class. Thyroid-related risk carries a black box warning based on animal data, though definitive human causality has not been established. Pancreatitis is a red flag - severe stomach pain radiating to the back requires stopping the drug and seeking immediate medical care.

One notable practical concern is muscle wasting. Registered dietitians and users consistently note that a meaningful portion of semaglutide-related weight loss includes lean tissue, which is particularly concerning for older populations or those trying to preserve or build muscle alongside fat loss. Ophthalmic safety concerns have also been reported in both clinical trials and observational studies, with the specific mechanisms still under investigation.

Where semaglutide fits

Semaglutide is the right choice when you want the compound with the longest track record, the most established safety data, FDA approval for both diabetes and weight management, a MASH indication, and a clear cardiovascular risk reduction benefit. It is also the most widely prescribed, which means the most clinical experience exists for managing its side effects. The trade-off is that pure GLP-1 agonism leaves the appetite-suppression and weight-loss ceiling lower than dual and triple agonists.

Tirzepatide: The Dual Agonist That Changed the Benchmark

Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is developed by Eli Lilly and works through both the GLP-1 and GIP receptors simultaneously. It is often called a "twincretin" - a synthetic molecule that activates both incretin receptors rather than just one.

How it works

Tirzepatide is described as an "imbalanced" agonist - it has higher affinity and potency at the GIP receptor than at the GLP-1 receptor. This matters because of the DZD finding noted above: in human pancreatic islets specifically, tirzepatide drives insulin secretion primarily through the GIP receptor, not the GLP-1 receptor. That mechanistic difference explains why tirzepatide outperforms pure GLP-1 agonists on glycemic control in humans, even though mouse models suggest GLP-1 receptor dominance.

Tirzepatide also displays biased agonism (selectively activating one downstream signaling pathway over another) toward the cAMP signaling pathway - a cellular messenger system that regulates insulin secretion - at the GLP-1 receptor. It preferentially engages that cAMP pathway over beta-arrestin recruitment (a separate signaling branch that tends to drive receptor internalization and signal dampening). This selective engagement may optimize metabolic efficacy. It also acts as a potent modulator of lipid storage in adipocytes - fat-storage cells - promoting nutrient storage in the fed state and supporting appropriate lipid release in the fasted state. This contributes to body-composition benefits beyond what caloric restriction alone would produce.

On the appetite and weight side, tirzepatide's dual receptor activity in the brain's appetite-regulating areas produces the most dramatic food-noise elimination of any compound in this comparison at standard clinical doses.

What the clinical data shows

The SURMOUNT trial program is the key reference. At the highest 15 mg weekly dose, tirzepatide produced up to 22.4% body weight reduction - exceeding the standard 2.4 mg semaglutide benchmark by a meaningful margin. The SURMOUNT trials used 5 mg, 10 mg, and 15 mg weekly doses, with a consistent dose-response pattern across all three.

Comparisons with semaglutide in the SURPASS program consistently showed tirzepatide superior on both HbA1c reduction and weight loss. The question was settled directly by SURMOUNT-5 (Aronne et al., New England Journal of Medicine, 2025), a randomized head-to-head trial of 751 adults with obesity and without type 2 diabetes. Over 72 weeks, tirzepatide at 10 or 15 mg produced 20.2% body weight reduction versus 13.7% for semaglutide at 1.7 or 2.4 mg. Gastrointestinal side effects leading to discontinuation were also less frequent on tirzepatide (2.7%) than semaglutide (5.6%).

Side-effect profile and food noise

Tirzepatide's GI side-effect profile is broadly similar to semaglutide's - nausea, constipation, diarrhea, and vomiting are the primary complaints - but tolerability appears somewhat better in practice, likely because GIP co-agonism partially offsets GLP-1-driven nausea. Ophthalmic safety concerns have been reported in large clinical trials for both semaglutide and tirzepatide, and the specific mechanisms remain under investigation.

Where tirzepatide most clearly separates from semaglutide is food noise. Food noise refers to the intrusive, constant preoccupation with food - thinking about what to eat, when to eat, counting calories obsessively, feeling driven toward specific foods even when not hungry. People using tirzepatide consistently describe a more complete and faster elimination of food noise than they experienced on semaglutide. This is likely a function of dual receptor engagement in the hypothalamic appetite-regulating regions, though the exact pharmacological basis is still being characterized.

Where tirzepatide fits

Tirzepatide is the right choice when appetite suppression and food-noise elimination are the primary goals, when you want the compound with the best head-to-head data against semaglutide, or when you have found semaglutide's ceiling insufficient. It is also FDA-approved for both diabetes and weight management, which makes it accessible through standard channels. The dual-agonist mechanism does not add a glucagon-driven fat-burning component the way retatrutide does, so raw weight-loss potential still falls below the triple agonist at higher doses.

Retatrutide: The Triple Agonist and Weight-Loss Ceiling-Breaker

Retatrutide is a triple agonist - it activates GLP-1, GIP, and the glucagon receptor simultaneously. It is developed by Eli Lilly, is currently in Phase 3 trials, and is not yet FDA-approved. It represents the current frontier of this compound class.

How it works

The triple receptor profile is what makes retatrutide categorically different from semaglutide and tirzepatide. GLP-1 and GIP handle the appetite suppression, insulin regulation, and metabolic homeostasis functions. The glucagon receptor adds something neither of the other two compounds can offer at comparable doses: a direct increase in energy expenditure and fat oxidation. Glucagon receptor agonism raises basal metabolic rate and drives the body to burn stored fat more aggressively - which is why retatrutide's weight-loss numbers look different from a dual agonist's numbers even when calorie reduction is similar.

The nuance here is that retatrutide's food-noise and appetite-suppression effect, while real, is generally reported as less pronounced than tirzepatide's at equivalent or lower doses. Tirzepatide's GIP-dominant dual agonism produces particularly strong hypothalamic appetite suppression. Retatrutide gets there too, but the glucagon receptor component shifts more of the weight-loss mechanism toward energy expenditure rather than appetite alone.

What the Phase 2 data shows

Phase 2 trial data showed retatrutide at the highest tested dose (12 mg weekly) producing approximately 24% body weight reduction over 48 weeks - higher than any comparable-duration tirzepatide result and substantially higher than standard semaglutide. Phase 3 trials are ongoing, and early signals are consistent with the Phase 2 picture.

The weight-loss velocity is also faster. Retatrutide users reach meaningful weight-reduction milestones earlier than semaglutide users do at equivalent weeks on therapy, likely because the energy-expenditure component starts contributing from early in the protocol rather than arriving late as a side effect of fat mass reduction.

Side-effect profile

Retatrutide shares the GI side-effect profile of the class - nausea, vomiting, diarrhea, constipation during escalation - with the addition of some glucagon-receptor-specific effects. Nausea appears dose-dependent and is generally managed through the same slow-escalation approach used for semaglutide and tirzepatide. Heart rate increases have been more prominently noted in Phase 2 retatrutide data than in tirzepatide data, which is worth monitoring as the Phase 3 dataset grows.

Because retatrutide is still in Phase 3 trials, the long-term safety database is thinner than what exists for the approved compounds. That is the honest trade-off: better efficacy data at higher doses, but less accumulated real-world safety observation.

How cagrilintide pairs with retatrutide and semaglutide

Cagrilintide is an amylin receptor agonist - a different mechanism entirely - developed by Novo Nordisk. Amylin is a pancreatic hormone that regulates satiety and gastric emptying, co-secreted with insulin. Cagrilintide mimics and extends amylin's effects.

The practical application: cagrilintide can be combined with semaglutide (the CagriSema combination) or theoretically with retatrutide to add a dedicated appetite-suppression layer that operates through a completely separate pathway. For someone on retatrutide who finds the food-noise effect insufficient compared to what tirzepatide users describe - which is a real and documented observation - adding cagrilintide provides amylin-pathway appetite suppression without changing the GLP/GIP/glucagon receptor balance.

CagriSema data is compelling. Phase 3 results show the combination producing weight loss in the range of 22 to 25% at 68 weeks, meaningfully exceeding what either component achieves alone. The combination stack trades simplicity for an additional mechanism, which also means additional side-effect surface area to monitor. For cases where maximum appetite suppression alongside maximum energy expenditure is the goal, the combination approach is increasingly how practitioners are thinking about the ceiling.

Where retatrutide fits

Retatrutide is the right choice when maximum weight loss is the primary goal and you are willing to work with a compound still in Phase 3 trials without full regulatory approval. It is also where practitioners are looking when someone has plateaued on tirzepatide or needs more than the dual agonist can deliver. The appetite-suppression experience is different from tirzepatide - not necessarily weaker at all doses, but driven by different mechanisms with a different qualitative feel.

Orforglipron: The Oral Small-Molecule GLP Option

Orforglipron is developed by Eli Lilly and represents a genuinely different category within this class. It is not a peptide at all - it is a small-molecule oral GLP-1 receptor agonist. This distinction matters practically.

How it works and why the format matters

Orforglipron activates the GLP-1 receptor through the same downstream mechanisms as semaglutide - insulin stimulation, glucagon suppression, gastric emptying delay, central appetite modulation - but it does so as an orally absorbed small molecule rather than an injected peptide. Oral semaglutide (Rybelsus) exists, but it requires administration under specific conditions (fasting, limited water, no food or other medications for 30 minutes after) and has lower bioavailability than injectable semaglutide. Orforglipron is absorbed without those constraints - a daily pill without the administration requirements.

That is the practical significance. Needle fear affects a substantial minority of adults - published prevalence estimates generally land somewhere between 10% and 30%, depending on how it is measured - and many more people simply prefer a daily pill to a weekly injection. For that group, orforglipron offers GLP-1 receptor agonism in a format that requires no injection at all.

What the Phase 3 data shows

The Phase 3 ATTAIN-1 trial enrolled 3,127 adults with obesity, or with overweight plus a weight-related condition and without diabetes, and compared 6 mg, 12 mg, and 36 mg orforglipron against placebo over 72 weeks. At the highest dose, participants lost an average of 12.4% of body weight versus 0.9% on placebo, with 59.6% losing at least 10% of body weight. That is lower than injectable tirzepatide or retatrutide, but it is meaningful weight loss in a format with substantially better daily usability for injection-averse populations. Glycemic control data in type 2 diabetes trials showed HbA1c reductions competitive with oral semaglutide. Regulatory submissions are underway.

Side-effect profile

GI side effects follow the class pattern - nausea, diarrhea, constipation, vomiting - and are generally consistent with what pure GLP-1 agonists produce. The small-molecule format does not appear to offer a tolerability advantage over peptide-based options; the side-effect surface area reflects the GLP-1 receptor mechanism regardless of delivery format.

Where orforglipron fits

Orforglipron is the right choice when the injectable format is the primary barrier and a pure GLP-1 receptor agonist mechanism is otherwise appropriate. It trades efficacy ceiling for accessibility. If your goal is maximum weight loss, this is not the compound. If your goal is meaningful metabolic improvement in a daily oral pill, this is currently the best option approaching regulatory approval.

Emerging GLP Peptides: Survodutide and Mazdutide

Two additional compounds deserve acknowledgment in any comprehensive GLP peptide comparison: survodutide and mazdutide. Both are dual agonists, both are in active clinical development, and both show promising data that positions them as potentially competitive with tirzepatide.

Survodutide (BI 456906)

Survodutide, developed by Boehringer Ingelheim and Zealand Pharma, is a dual GLP-1 and glucagon receptor agonist - which makes it mechanistically more similar to retatrutide than to tirzepatide. It activates GLP-1 for appetite suppression and insulin regulation, and the glucagon receptor for energy expenditure and fat oxidation. Notably, it does not include the GIP component that defines tirzepatide's dual agonist profile.

Survodutide has now reported Phase 3 data. In the SYNCHRONIZE-1 trial, it produced sustained weight loss averaging up to 16.6% at 76 weeks in people with obesity or overweight - meaningful efficacy that places it between standard-dose semaglutide and tirzepatide rather than ahead of them. It is also in development for MASH (metabolic-dysfunction-associated steatohepatitis - a form of fatty liver disease where fat buildup causes inflammation and scarring), where the GLP-1 plus glucagon receptor combination has direct liver benefit that pure incretin agonists do not.

The side-effect picture for survodutide tracks the class pattern: GI-dominant adverse effects, dose-dependent nausea during escalation. The glucagon receptor component adds some cardiovascular monitoring considerations around heart rate, consistent with what is observed in retatrutide data.

Mazdutide (IBI362)

Mazdutide, developed by Innovent Biologics, is also a dual GLP-1 and glucagon receptor agonist. Phase 3 data from trials conducted primarily in Chinese populations has shown weight-loss results in the range of 14 to 19% over 48 weeks at 6 mg weekly dosing - competitive with tirzepatide and positioned between standard semaglutide and tirzepatide in terms of efficacy. HbA1c reduction data in type 2 diabetes trials has been similarly competitive.

Mazdutide's regulatory trajectory is primarily in China, where it has received priority review designation. International regulatory filings are a future question rather than an imminent one. For audiences evaluating GLP options in Western markets, mazdutide is best understood as a demonstration that the GLP-1 plus glucagon dual agonist combination produces competitive weight loss to tirzepatide through a different receptor pair - which has real implications for how the class develops as more compounds enter this space.

GLP Peptide Head-to-Head: How They Stack Up

Here is the practical comparison across the dimensions that matter most for decision-making.

Weight-loss efficacy

Ranked by peak clinical trial weight loss at highest studied doses and longest available follow-up:

• Retatrutide leads the class at approximately 24.2% body weight reduction over 48 weeks (Phase 2, 12 mg weekly)
• Tirzepatide follows at up to 22.4% (SURMOUNT trials, 15 mg weekly); in the SURMOUNT-5 head-to-head it reached 20.2% at 72 weeks against semaglutide's 13.7%
• Semaglutide at approved 2.4 mg reaches approximately 15% over 68 weeks; the investigational 7.2 mg dose showed 20.7% (STEP UP trial)
• Survodutide reached up to 16.6% at 76 weeks (Phase 3, SYNCHRONIZE-1)
• Mazdutide shows approximately 14 to 19% over 48 weeks (Phase 3 Chinese trials)
• Orforglipron at 12.4% over 72 weeks (Phase 3, ATTAIN-1) - lower ceiling, oral format advantage

The weight-loss story is not just about peak numbers. Rate of loss and body-composition effects matter too. Retatrutide's glucagon-receptor-driven energy expenditure produces faster early weight loss than pure appetite suppression does. Tirzepatide's direct adipocyte (fat-storage cell) modulation through the GIP receptor produces body-composition effects - specifically, favorable lean mass preservation alongside fat mass reduction - that go beyond what caloric restriction alone achieves.

Appetite suppression and food noise

This is where the community and clinical pictures converge most clearly.

Tirzepatide produces the most complete food-noise elimination at standard clinical doses. The GIP-dominant dual agonism appears to create a particularly strong hypothalamic effect. People describe not thinking about food between meals at all - not suppression of cravings, but the absence of food thought as a baseline.

Semaglutide produces meaningful food-noise reduction and is highly effective for most people. At lower or maintenance doses, some users describe partial rather than complete quieting of food noise, particularly when the dose stays at 1.0 mg rather than escalating to 2.4 mg.

Retatrutide produces appetite suppression through both GLP-1 and GIP receptor engagement - the same two mechanisms as tirzepatide - but the qualitative experience is reported as somewhat less dramatic on food noise specifically, particularly at mid-range doses. At higher doses (8 mg and above in Phase 2), appetite suppression is substantial. The glucagon component may shift the subjective experience of weight loss toward feeling like one is burning energy rather than feeling like one does not want food.

Adding cagrilintide to semaglutide or retatrutide shifts the appetite-suppression picture meaningfully. For someone on either of those compounds who wants the food-noise benefit that tirzepatide's GIP-dominant agonism provides, cagrilintide addresses that gap through amylin-pathway mechanisms rather than receptor profile changes.

GI tolerability

All compounds in this class share the same fundamental GI side-effect profile during escalation: nausea, vomiting, diarrhea, constipation. The differences are at the margins.

• Tirzepatide appears somewhat better tolerated on nausea than semaglutide, likely because GIP co-agonism partially offsets GLP-1-driven nausea
• Semaglutide has the most documented tolerability-management strategies because it has been prescribed longest
• Retatrutide shows comparable GI tolerability to tirzepatide in Phase 2 data, with some additional monitoring needed for glucagon-receptor-related cardiovascular signals, particularly heart rate elevation
• Orforglipron, survodutide, and mazdutide share the class GI pattern without a clear tolerability advantage demonstrated over the approved injectable options

Practical approaches that reduce GI severity for most people across the class: smaller portions, avoiding high-fat meals around injection time, maintaining hydration, and prioritizing protein intake.

Format and accessibility

Choosing Based on Your Primary Goal

There is no universal best compound. The right choice depends on what you are optimizing for.

If your primary goal is maximum weight loss and you are willing to use an investigational compound: Retatrutide at higher doses currently offers the highest weight-loss ceiling of any single compound, with Phase 3 data expected to confirm what Phase 2 showed. Adding cagrilintide to retatrutide further extends both appetite suppression and total efficacy.

If your primary goal is food-noise elimination and appetite suppression: Tirzepatide is currently the clearest choice at FDA-approved doses. The GIP-dominant dual agonism produces the most consistently reported and most complete food-noise reduction in the class. Cagrilintide's complementary benefit is greatest where appetite suppression is the gap - as with semaglutide or retatrutide - not where tirzepatide's GIP agonism already delivers strong food-noise elimination.

If your primary goal is metabolic health and cardiovascular risk reduction: Semaglutide has the most robust cardiovascular outcomes data, including an approved indication for reducing heart attack, stroke, and cardiovascular death in type 2 diabetes patients with established heart disease. If you have established cardiovascular disease and type 2 diabetes, semaglutide's outcomes data is the strongest foundation.

If your primary goal is avoiding injections entirely: Orforglipron is the best current option approaching regulatory approval for a fully injection-free GLP-1 experience. The efficacy ceiling is lower, but the format removes the injection barrier completely.

If you are managing MASH or liver disease alongside weight and metabolic goals: Survodutide has the most development activity specifically targeting MASH alongside weight loss. Semaglutide is also approved for MASH, making it an option for anyone who wants an approved compound covering both indications simultaneously.

If you are considering a combination approach: CagriSema (cagrilintide plus semaglutide) is the most clinically developed combination with Phase 3 results showing outcomes approaching what retatrutide achieves as a single compound. Cagrilintide plus retatrutide is a logical combination for maximum appetite suppression plus maximum energy expenditure, but it is further from established clinical data at this point.

GLP Peptide Comparison: Frequently Asked Questions

What is the difference between semaglutide and tirzepatide in simple terms?

Semaglutide activates one receptor (GLP-1), while tirzepatide activates two (GLP-1 and GIP). The dual receptor engagement gives tirzepatide stronger appetite suppression and food-noise elimination at equivalent clinical doses, better body-composition outcomes through direct fat-cell modulation, and slightly better GI tolerability in practice. Both are FDA-approved; tirzepatide generally outperforms semaglutide on weight loss and metabolic markers in comparative trial data.

Is retatrutide available yet?

Retatrutide is currently in Phase 3 clinical trials and is not FDA-approved. Phase 2 data showed approximately 24% weight loss at the highest studied dose over 48 weeks, and Phase 3 results are expected to confirm that picture. People currently accessing retatrutide are doing so outside standard prescription channels or through investigational trial participation, not through standard pharmacy dispensing.

Why do some people switch from semaglutide to tirzepatide?

The most common reasons are wanting stronger food-noise elimination, hitting a weight-loss plateau on semaglutide, or wanting the improved tolerability profile that tirzepatide's GIP component appears to provide. Many people find semaglutide effective but describe a partial rather than complete quieting of food noise - particularly at maintenance doses - and switching to tirzepatide often resolves that gap.

What is food noise and which compound eliminates it best?

Food noise refers to the intrusive, background mental preoccupation with food - constant thoughts about what to eat, when to eat, counting calories, or feeling driven toward specific foods even when not hungry. Among currently available options, tirzepatide produces the most consistently reported and most complete food-noise elimination. Semaglutide reduces it substantially but not always completely at standard doses. Retatrutide produces strong appetite suppression but the food-noise experience is reported as somewhat different qualitatively, likely because more of its weight-loss mechanism runs through energy expenditure rather than appetite-center suppression.

Can you combine these GLP peptides with other compounds?

The most studied combination is cagrilintide plus semaglutide (CagriSema), which adds amylin-pathway appetite suppression to GLP-1 receptor agonism and shows Phase 3 results in the 22 to 25% weight-loss range. Cagrilintide can theoretically be paired with retatrutide to address the appetite-suppression gap while maintaining the triple agonist's energy-expenditure advantages. Combining two GLP receptor agonists with overlapping receptor targets generally does not add meaningful benefit and compounds the side-effect surface area without proportional efficacy gain.

Does orforglipron work as well as injectable semaglutide?

Not quite, based on current Phase 3 data. Orforglipron produced 12.4% weight loss over 72 weeks at its highest dose in ATTAIN-1, compared to approximately 15% for injectable semaglutide at 2.4 mg over 68 weeks. The efficacy gap reflects the difference between oral small-molecule and injectable peptide delivery at currently studied doses. The trade-off is format - orforglipron requires no injection, no food restriction windows, and no storage considerations, which is a meaningful accessibility advantage for the population that finds the injectable format prohibitive.

What happens if you stop taking a GLP peptide?

Weight regain is the primary documented concern. Clinical follow-up data from the STEP trials showed that participants who stopped semaglutide regained a substantial portion - up to roughly two-thirds - of lost weight over the following year if they did not maintain significant lifestyle changes. The appetite-regulating and metabolic effects of these compounds are pharmacological, meaning they attenuate when the drug clears the system. Planning for the cessation question - whether that means transitioning to lifestyle-only maintenance, considering a lower maintenance dose, or understanding that long-term use may be needed for sustained outcomes - is an important part of the protocol conversation.

The Bottom Line on GLP Peptide Selection

This class of compounds has fundamentally changed what is possible for weight management and metabolic health. The conversation has moved from "does this work" - it does - to "which one works best for my specific situation."

Tirzepatide currently holds the advantage for most people who have access to approved options and are primarily concerned with appetite suppression and weight loss. Its dual agonism produces better outcomes than semaglutide in comparative data, and the food-noise elimination effect is the clearest differentiator in real-world use.

Retatrutide is where things get genuinely interesting if maximum efficacy is the goal. The triple agonist profile produces weight-loss numbers that dual and single agonists cannot match at equivalent doses, and the Phase 3 data should confirm whether Phase 2's signals hold. The trade-off is no regulatory approval yet and a thinner long-term safety database.

Semaglutide remains the foundation. It has the most clinical experience behind it, the most established side-effect management strategies, the only cardiovascular outcomes indication in the class, and an approved MASH indication that none of the others carry yet. If you are working within standard prescription channels or need the deepest evidence base, it is not the wrong choice - it is just not the highest ceiling anymore.

And if the needle is the barrier, orforglipron's arrival as an oral small-molecule GLP-1 agonist will meaningfully expand who can access this class of compounds without that trade-off.

This article gives you the landscape. What it cannot do is tell you which compound fits your specific history, goals, body weight, and health picture - because that is a personalization question, not an educational one. Create a free MyPeptidePal account to build a protocol customized to your goals and compound choice. It takes under 60 seconds and gives you a starting point grounded in your situation, not a generic recommendation.